Antigen-specific immunotherapies for acute myeloid leukemia
SA Buckley, RB Walter - Hematology 2014, the American …, 2015 - ashpublications.org
Antigen-specific immunotherapies have emerged as important components of curative
treatment algorithms for many cancers. In acute myeloid leukemia (AML), success has been …
treatment algorithms for many cancers. In acute myeloid leukemia (AML), success has been …
Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?
A Rashidi, RB Walter - Expert review of hematology, 2016 - Taylor & Francis
Antigen-specific immunotherapies have long been pursued as a means to improve the
outcomes of patients with acute myeloid leukemia (AML). Success thus far has been limited …
outcomes of patients with acute myeloid leukemia (AML). Success thus far has been limited …
[HTML][HTML] Anti-CD117 immunotherapy to eliminate hematopoietic and leukemia stem cells
Precise replacement of diseased or dysfunctional organs is the goal of regenerative
medicine and has appeared to be a distant goal for a long time. In the field of hematopoietic …
medicine and has appeared to be a distant goal for a long time. In the field of hematopoietic …
The role of CD33 as therapeutic target in acute myeloid leukemia
RB Walter - Expert opinion on therapeutic targets, 2014 - Taylor & Francis
CD33 is a myeloid differentiation antigen that is displayed on acute myeloid leukemia (AML)
blasts in most patients and, possibly, leukemic stem cells in some, and has thus served as …
blasts in most patients and, possibly, leukemic stem cells in some, and has thus served as …
Update on antigen-specific immunotherapy of acute myeloid leukemia
SA Buckley, RB Walter - Current hematologic malignancy reports, 2015 - Springer
Among the few drugs that have shown a benefit for patients with acute myeloid leukemia
(AML) in randomized clinical trials over the last several decades is the CD33 antibody-drug …
(AML) in randomized clinical trials over the last several decades is the CD33 antibody-drug …
Reinforcing the primary immunotherapy modulators against acute leukemia; monoclonal antibodies in AML
Recent therapeutic advances in cancer treatment recruit immune system potentiation
against malignant cells. Numerous ongoing clinical trials on immunotherapy methods, either …
against malignant cells. Numerous ongoing clinical trials on immunotherapy methods, either …